Head-to-head evidence
BNT351 vs Lotivibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV envelope · full HIV pipeline
BNT351
Developed by BioNTech
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2026 · NCT07392372 (registry estimate)
Lotivibart
Developed by ViiV Healthcare
NCT04871113 · Phase 2 · completed
Participants were randomized among dose cohorts, but the study was open-label, had no placebo or active comparator during monotherapy, and included only 6 to 16 participants per cohort. The primary endpoint was the surrogate measure of maximum decline in HIV-1 RNA and was reported descriptively without a formal comparative efficacy test, so the findings do not establish comparative treatment benefit.
Next expected readout: January 2027 · NCT07053384 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BNT351's landscape · Lotivibart's landscape